Through the deal, each Henry Schein shareholder as of September 1 will receive a dividend of 1 additional share for every share held, with trading beginning on a split-adjusted basis on September 15.
Henry Schein touted the split as its 2nd since its IPO in 1995, with its 1st 2-for-1 split in February 2005. With the split, the Melville, N.Y.-based company will have approximately 158 million shares outstanding.
“Our market capitalization and share price have increased considerably over the past dozen years as we have expanded and diversified our business in the U.S. and in certain international markets. We believe this stock split is a testament to our success, and will increase liquidity and make equity ownership in Henry Schein more accessible,” CFO & exec VP Steven Paladino said in a press release.
Shares in Henry Schein are up 0.5% today, at $168.76 as of 11:20 a.m. EDT.
Last December, Henry Schein said it made an 80% equity investment in Polish full-service dental distributor Marrodent.
Warsaw, Poland-based Marrodent was founded in 1990, and recorded 2015 sales of approximately $32 million, according to Henry Schein. The company employs 60 sales representatives, and serves approximately 10,000 office-based dental practitioners in the region.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.